| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8441172 | European Journal of Cancer | 2016 | 7 Pages |
Abstract
Bias in reporting of efficacy outcomes is common for studies with a negative primary end-point and can lead to off-label misuse of experimental therapies, if they are approved for other indications. Toxicity is under-reported, especially for studies with a positive primary end-point, leading to a biased view of the safety of new treatments.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Francisco E. Vera-Badillo, Marc Napoleone, Monika K. Krzyzanowska, Shabbir M.H. Alibhai, An-Wen Chan, Alberto Ocana, Bostjan Seruga, Arnoud J. Templeton, Eitan Amir, Ian F. Tannock,